X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
EMWA 2024
Not Confirmed
Contact Supplier
Details:
Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicological studies.
Lead Product(s): Cannabidiol,Isoflurane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Incannex Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
EMWA 2024
Not Confirmed
Contact SupplierDetails:
MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients diagnosed with dementia and agitation.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: T2:C100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2022
EMWA 2024
Not Confirmed
Contact SupplierDetails:
New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Lead Product(s): Cannabigerol,Cannabidiol
Therapeutic Area: Neurology Product Name: CBG:CBD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Lead Product(s): Cannabidiol,Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
EMWA 2024
Not Confirmed
Contact SupplierDetails:
McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial.
Lead Product(s): Cannabidiol
Therapeutic Area: Sleep Product Name: CBD50
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 21, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA, distributed through STADAPHARM, a direct subsidiary of STADA.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: CannabiSTADA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
As a result of agreement, patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA (cannabidiol), distributed through STADAPHARM, a direct subsidiary of STADA.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: CannabiStada
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
LPT CBD (cannabinoid) is a loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. It is being evaluated for the treatment for chronic pain management.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: LPT-CBD
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol
Therapeutic Area: Musculoskeletal Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 18, 2024
Details:
RHO Phyto Micro Drop 100, a 10% CBD (THC free) is a proprietary oral formulation of cannabidiol, which is a CB1 receptor negative allosteric modulator. It is indicated for the treatment of seizures related to Lennox-Gastaut Syndrome and Dravet Syndrome.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
The agreement facilitates Innocan to initiate the FDA approval process for its liposome CBD platform (LPT-CBD), facilitating prolonged and controlled release of CBD into the blood stream. It is being evaluated for the treatment of epilepsy and for pain management.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: LPT-CBD
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hebrew University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 25, 2024
Details:
Under the agreement, GenBio will license potentially new, next generation of anti-inflammatory cannabinoids to be included in Strainsforpains CBD branded products.
Lead Product(s): Cannabidiol
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Strainsforpains
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2024
Details:
The acquisition expands Branded Legacy's portfolio ranging from gummies to compression sleeves and pain-relieving topical creams, including Relief Gummy, which contains a balanced ratio of CBD to Nano Delta-9-THC.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Relief Gummy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Branded Legacy, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 12, 2024
Details:
EmpowerCBD (cannabidiol oral solution) is a CB1 receptor negative allosteric modulator. It is being evaluated for the treatment of social anxiety disorder.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: EmpowerCBD
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
SCI-210 a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated for the treatment of Autism Spectrum Disorder in children between 5 and 18 years.
Lead Product(s): Cannabidiol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2024
Details:
LPT-CBD (cannabidiol) is a CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of patients suffering from neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: LPT-CBD
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
DehydraTECH-CBD (cannabidiol) is a DehydraTECH-processed CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of diabetes and weight loss.
Lead Product(s): Cannabidiol
Therapeutic Area: Nutrition and Weight Loss Product Name: DehydraTECH-CBD
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
SCI- 210 consisits of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA (palmitoylethanolamide). It is being developed for the treatment of Autism Spectrum Disorder.
Lead Product(s): Palmitoylethanolamide,Cannabidiol
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
ProZ-001 (cannabidiol) is a CB1 receptor negative allosteric modulator, which is approved for the treatment of patients with dravet syndrome and lennox-gastaut syndrome.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: ProZ-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
LPT CBD (cannabinoid) is a loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. It is being evaluated for the treatment of epilepsy and for pain management.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: LPT-CBD
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
Lipid-CBD (cannabidiol) is a CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of patients suffering from neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Lipid-CBD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Trunerox (cannabidiol) is a CB1 receptor negative allosteric modulator, which is approved for the treatment of patients with dravet syndrome and lennox-gastaut syndrome.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Trunerox
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The exclusive supply agreement is for the Company’s proprietary topical products that have been commercialized in the Canadian market under the RHO Phyto brand, including AVCN-583601, Ultra-CBD cream, a CBD localized cream developed to target dermatology conditions.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Product Name: AVCN-583601
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 05, 2024
Details:
SCI-210 (cannabidiol) is a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated in clinical trials for the treatment of autism spectrum disorder.
Lead Product(s): Cannabidiol,Cannamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Under the agreement, Sipp Industries will manufacture SinuSave® CBD Nasal Spray products. SinuSave® CBD is proven to be bacteriostatic and bactericidal.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: SinuSave
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SinuSave
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 23, 2024
Details:
The company is aiming to concentrate on the clinical advancement of THC:CBD (Tetrahydrocannabinol), a partial agonist of the CB1 receptor with Cannabidiol. Both controlled substances will undergo evaluation for the treatment of chemotherapy-induced neuropathic pain.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: THC:CBD
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: German Pain Association
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2024
Details:
Clasepi (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It has been launched in India for the treatment of patients with Epilepsy.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Clasepi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2024
Details:
Clasepi is a prescription cannabidiol (CBD) specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older. It is now approved for Epilepsy in India.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Clasepi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
SAP021 (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It is being evaluated in phase 1 clinical trials for the treatment of neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: SAP021
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
SAP021 is an orally administered cannabinoid. It is under phase 1 clinical development for the treatment of neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: SAP021
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2023
Details:
Epidiolex (cannabidiol) is an oral CB receptor CB1 receptor negative allosteric modulator. It is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Product Name: Epidiolex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2023
Details:
SAP021 (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It is being evaluated in phase 1 clinical trials for the treatment of neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: SAP021
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.
Lead Product(s): Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area: Musculoskeletal Product Name: Trichomylin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Cannabidiol is a CB1 receptor negative allosteric modulator (NAM), which is being evaluated in preclinical studies for the treatment of Pain.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
The Company intends to use the net proceeds to fund the Company's pre-investigational new drug meeting regarding the human application of the Company's products, including Cannabidiol.
Lead Product(s): Cannabidiol
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 20, 2023
Details:
The Company intends to use the net proceeds from the Offering to fund the Company's pre-investigational new drug meeting with the United States FDA regarding the human application and expansion of the Company's derma-cosmetic product distribution.
Lead Product(s): Cannabidiol,Menthol,Camphor
Therapeutic Area: Neurology Product Name: Relief & Go
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Private Placement October 12, 2023
Details:
Through the acquisition, Harmony gets the opportunity to advance the development of a treatment for the symptoms of Fragile X syndrome and other rare neuropsychiatric disorders including, Zygel, the first and only pharmaceutically manufactured, synthetic cannabidiol.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harmony Biosciences
Deal Size: $200.0 million Upfront Cash: $200.0 million
Deal Type: Acquisition October 11, 2023
Details:
SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Lead Product(s): Cannabidiol,Cannamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
Endosane is focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of Cannabidiol can be achieved with this technology.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endosane Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Cannabidiol, a chemical compound from the cannabis plant, that help improvement in social and motor problems, a reduction in epilepsy and an increase in life expectancy in Leigh syndrome mouse models.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.
Lead Product(s): Cannabidiol
Therapeutic Area: Podiatry Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
Through the acquisition, Harmony gets the opportunity to advance the development of a treatment for the symptoms of Fragile X syndrome and other rare neuropsychiatric disorders including, Zygel, the first and only pharmaceutically manufactured, synthetic cannabidiol.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harmony Biosciences
Deal Size: $200.0 million Upfront Cash: $200.0 million
Deal Type: Acquisition August 14, 2023
Details:
The agreement aims to perform a clinical pharmacology study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hebrew University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 07, 2023
Details:
The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.
Lead Product(s): Tetrahydrocannabinol Analog,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1A
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kingswood Investments
Deal Size: $8.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 07, 2023
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Details:
The proceeds will be used for production, raw material and laboratory costs associated with production of GMP cannabinoid medicines CannEpil, a high-CBD, low-THC formulation delivered by an oral mucosal solution and CogniCann, an oral spray that combines THC and CBD.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: CannEpil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oberon Capital
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Financing August 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
